Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report

INTRODUCTION: Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options. Angiogenesis plays a fundamental role in the development of drug-resistance in ovarian cancer. Anlotinib, a novel oral multi-targeted tyrosine kinase inhibitor which targets a board...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Li, Yang, Meng, Zhang, Xuan, Li, Hua, Wu, Lingying, Zhang, Yuzi, Cai, Shangli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253621/
https://www.ncbi.nlm.nih.gov/pubmed/32443311
http://dx.doi.org/10.1097/MD.0000000000020053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253621/
https://www.ncbi.nlm.nih.gov/pubmed/32443311
http://dx.doi.org/10.1097/MD.0000000000020053

Ejemplares similares